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Abstract
Background: Somatic amplifications of the LYL1 gene are relatively common occurrences in patients who develop
uterine corpus endometrial carcinoma (UCEC) as opposed to other cancers. This study was undertaken to determine
whether such genetic alterations affect survival outcomes of UCEC.
Methods: In 370 patients with UCEC, we analysed clinicopathologic characteristics and corresponding genomic
data from The Cancer Genome Atlas database. Patients were stratified according to LYL1 gene status, grouped as
amplification or non-amplification. Heightened levels of cancer-related genes expressed in concert with LYL1
amplification were similarly investigated through differentially expressed gene and gene set enrichment analyses.
Factors associated with survival outcomes were also identified.
Results: Somatic LYL1 gene amplification was observed in 22 patients (5.9%) with UCEC. Patients displaying
amplification (vs. non-amplification) were significantly older at the time of diagnosis and more often were marked by
non-endometrioid, high-grade, or advanced disease. In survival analysis, the amplification subset showed poorer
progression-free survival (PFS) and overall survival (OS) rates (3-year PFS: 34.4% vs. 79.9%, P = 0.031; 5-year OS: 25.1% vs.
84.9%, P = 0.014). However, multivariate analyses adjusted for tumor histologic type, grade, and stage did not confirm
LYL1 gene amplification as an independent prognostic factor for either PFS or OS. Nevertheless, MAPK, WNT, and cell
cycle pathways were significantly enriched by LYL1 gene amplification (P < 0.001, P = 0.002, and P = 0.004, respectively).
Conclusions: Despite not being identified as an independent prognostic factor in UCEC, LYL1 gene amplification is
associated with other poor prognostic factors and correlated with upregulation of cancer-related pathways.
Keywords: Endometrial Neoplasms, The Cancer Genome Atlass, LYL1s, Survival analysiss, Gene expression pattern analysis,
Gene set enrichment analysis
Background
Uterine corpus endometrial cancer (UCEC) imposes a
global burden in both developed and developing
countries [1]. In the United States, it is the most
common gynecologic malignancy, accounting for 61,380
new cases in 2017 [2]. In Korea, the incidence of
UCEC is clearly increasing and is estimated to comprise
2.5% (2578) of all new female cancers in 2017 [3, 4].
In 2013, The Cancer Genome Atlas (TCGA) Research
Network issued an integrated report of genomic, tran-
scriptomic, and proteomic profiles in 373 patients diag-
nosed with UCEC [5]. Furthermore, this consortium
determined four prognostic categories (good→poor as
shown) for classification of UCEC: (1) polymerase ɛ
(POLE) ultramutated; (2) microsatellite instability (MSI)
hypermutated; (3) low copy number; and (4) high copy
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number. The high copy number group in particular in-
cludes most of the serous and serous-like endometrioid
tumors, sharing genomic features with ovarian serous
carcinomas. Researchers have since incorporated these
molecular criteria into clinical trials designed to gauge
postsurgical adjuvant treatment of UCEC (https://doi.
org/10.1186/ISRCTN11659025).
In keeping with the era of precision medicine, discov-
ery of reliable genetic changes is essential to provide
individualized treatment of patients with UCEC [5, 6].
Little-known genes such as LYL1 may now be identified
as novel prognostic indicators or as potential thera-
peutic targets. The LYL1 gene is located on the short
(p) arm of chromosome 19 at position 13.13, where it
encodes a protein implicated in blood vessel maturation
and haematopoiesis [7]. As a member of basic helix-
loop-helix transcription factor family, the LYL1 gene is
also known to regulate cell proliferation and differenti-
ation [8], and a form of T-cell acute lymphoblastic leu-
kaemia has been linked to a chromosomal aberration of
LYL1 [7].
Curiously, somatic amplifications of the LYL1 gene fre-
quently accompany UCEC, more so than most other
cancers, ranking second among TCGA listings. However,
its ramifications in this setting have yet to be fully
explored. The current study, entailing TCGA database
analysis, was undertaken to determine whether genetic
alterations in the LYL1 gene (such as amplification) may
impact survival outcomes in patients with UCEC.
Methods
Data acquisition
We downloaded genomic alteration data on patients
with UCEC and corresponding clinicopathologic pro-
files at the Genomics Data Commons (https://portal.
gdc.cancer.gov) and cBioPortal for Cancer Genomics
(http://www.cbioportal.org) web portals. The Illumina
Genome Analyzer served as platform for DNA sequencing
(Illumina Inc., San Diego, CA, USA). This study complied
with TCGA publication guidelines and policies (http://
cancergenome.nih.gov/publications/publicationguidelines).
The Institutional Review Board of Seoul National
University Hospital ruled that no formal ethics ap-
proval was required in this study.
Study population
In total, 370 patients with UCEC qualified for this study.
The clinicopathologic data collected included age,
underlying comorbidities, International Federation of
Gynecology and Obstetrics (FIGO) stage, tumor histo-
logic type and grade, and treatment of UCEC (ie, sur-
gery, radiation, chemotherapy). Tumor MSI status was
also collected. Patients were assigned to LYL1 gene amp-
lification and non-amplification groups as warranted.
Bioinformatics analysis
LYL1 gene status, especially whether it was amplified,
was determined through the cBioPortal for Cancer
Genomics (http://www.cbioportal.org). Level-3 data of pa-
tients with UCEC and raw reads (HTSeq-counts) of differ-
entially expressed gene (DEG) analyses were accessed via
FireBrowse (http://firebrowse.org). The Kyoto Encyclopedia
of Genes and Genomes (KEGG) pathway analysis of gene
expression data [9] was subjected to Gene Set Enrichment
Analysis (GSEA) [10]. For visualization of enrichment path-
way, the NetworkAnalyst (http://www.networkanalyst.ca)
was used [11].
In doing so, the Search Tool for the Retrieval of Inter-
acting Genes/Proteins (STRING) database was applied,
achieving confidence scores of 400–1000 [12]. DEGs
were identified through open-source software analysis
(R package DESeq2; http://www.bioconductor.org) [13].
Statistical analysis
To compare clinicopathologic features of the two patient
subsets, Student’s t-test and Mann-Whitney U-test were
applied to continuous variables, and Pearson’s chi-
squared and Fisher’s exact tests for categorical variables.
We defined PFS as the time elapsed between date of
initial diagnosis and date of disease progression, whereas
overall survival (OS) represented the time interval be-
tween date of initial diagnosis and date of cancer-related
death or end of study. Survival estimates were generated
via Kaplan-Meier method and log-rank test. Cox propor-
tional hazards regression models were engaged to calcu-
late hazard ratios (HRs) and 95% confidence intervals
(CIs). For survival analytics, we relied on commercially avail-
able software (SPSS v21.0; IBM, Armonk, NY, USA). Open-
source programming (R v2.12.1, ISBN 3–900,051–07-0,
http://www.R-project.org; R Foundation for Statistical
Computing, Vienna, Austria) was used for all other com-
putations. Statistical significance was set at P < 0.05.
Results
Somatic copy number variations in UCEC
Frequencies of somatic amplifications involving the
LYL1 gene are depicted according to TCGA classifica-
tion in Fig. 1a. UCEC ranked second among cancers
in terms of LYL1 gene amplification. In genomic
alteration analyses, chromosomes 1q, 3q, 8q, 17q, and
19p were frequently amplified in this patient popula-
tion (Fig. 1b). The LYL1 gene of 19p arm was
amplified in 5.9% (22/370) of patients with UCEC.
Additionally, the LYL1 gene was one of the 15 mostly
amplified oncogenes filtered by gene family in GSEA
(Fig. 1c). Meanwhile, the 15 mostly deleted tumor
suppressor genes, including PTEN, are displayed in
Fig. 1d.
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Characteristics of patients with UCEC
Patients’ clinicopathologic characteristics are presented
in Table 1. Mean patient age was 63 years. Of the 370 pa-
tient participants, 304 (82.2%), 52 (14.1%), and 14 (3.8%)
displayed endometrioid, serous, and mixed histologic
types of UCEC, respectively. Members of the LYL1 ampli-
fication (vs. non-amplification) group were significantly
older at time of diagnosis and more often exhibited bio-
logically aggressive tumors, marked by advanced-stage dis-
ease (FIGO stage III-IV; P = 0.003), high-grade malignancy
(grade 3; P < 0.001), and serous histologic type (P < 0.001).
Proportions of the four TCGA categories of UCEC also
showed comparative differences, with 72.7% of amplifica-
tion group members achieving high copy number rank,
versus 12.1% in the non-amplification group (P < 0.001).
In terms of adjuvant treatment, chemotherapy recipients
were more numerous in LYL1 amplification group than in
non-amplification group (50.0% vs 28.4%; P = 0.032)
(Table 1).
Between-group comparisons of survival outcomes and
identification of prognostic factors
During the observation period (median, 23.9 months;
range, 0.5–191.7 months), 5 patients in the amplification
group and 34 in the non-amplification group died of
their disease. Survival analysis indicated poorer 3-year
PFS (34.4% vs. 79.9%; P = 0.031) and 5-year OS (25.1%
vs. 84.9%; P = 0.014) in the amplification (vs. non-
amplification) group (Fig. 2).
LYL1 gene amplification also showed a significant as-
sociation with poor OS in univariate analysis (P = 0.019)
(Table 2). However, after adjusting for variables such as
histologic type, grade, and FIGO stage, LYL1 gene status
was not confirmed as a significant prognostic factor in
Fig. 1 Analysis of gene amplification in various cancer types and uterine corpus endometrial carcinoma: a frequencies of copy number variations
across chromosomes; b frequencies of LYL1 gene amplification in various cancer types; c correlations between amplification frequencies and
mortality across top 15 oncogenes; and (d) correlations between deletion frequencies and mortality across top 15 tumor suppressor genes in
uterine corpus endometrial carcinoma
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Table 1 Clinicopathologic characteristics of patients
Characteristics All (n = 370, %) LYL1 amplification (n = 22, %) LYL1 non-amplification (n = 348, %) P
Age, years < 0.001
Mean ± SD 63.1 ± 11.0 72.7 ± 8.0 62.5 ± 10.9
Menopausea 0.393
Yes 313 (84.6) 0 (0) 27 (7.8)
No 27 (7.3) 21 (95.5) 292 (83.9)
Unknown 30 (8.1) 1 (4.5) 29 (8.3)
Diabetes 0.774
Yes 83 (22.4) 5 (22.7) 78 (22.4)
No 221 (59.7) 11 (50.0) 210 (60.3)
Unknown 66 (17.8) 6 (27.3) 60 (17.2)
Hypertension 0.420
Yes 195 (52.7) 11 (50.0) 184 (52.9)
No 135 (36.5) 5 (22.7) 130 (37.4)
Unknown 40 (10.8) 6 (27.3) 34 (9.8)
Histologic type < 0.001
Endometrioid 304 (82.2) 6 (27.3) 298 (85.6)
Serous 52 (14.1) 13 (59.1) 39 (11.2)
Mixed 14 (3.8) 3 (13.6) 11 (3.2)
Grade < 0.001
1 88 (23.8) 0 (0) 88 (25.3)
2 106 (28.6) 1 (4.5) 105 (30.2)
3 176 (47.6) 21 (95.5) 155 (44.5)
FIGO stage 0.003
I 254 (68.6) 9 (40.9) 245 (70.4)
II 24 (6.5) 2 (9.1) 22 (6.3)
III 72 (19.5) 9 (40.9) 63 (18.1)
IV 17 (4.6) 2 (9.1) 15 (4.3)
Unknown 3 (0.8) 0 (0) 3 (0.9)
TCGA type
POLE ultra-mutated 17 (4.6) 0 (0) 17 (4.9) 0.612
MSI hyper-mutated 65 (17.6) 0 (0) 65 (18.7) 0.019
Low copy number 90 (24.3) 0 (0) 90 (25.9) 0.006
High copy-number 58 (15.7) 16 (72.7) 42 (12.1) < 0.001
Indeterminate 140 (37.8) 6 (27.3) 134 (38.5) 0.292
MSI status < 0.001
Stable 223 (60.2) 22 (100.0) 201 (57.8)
Low 19 (5.1) 0 (0) 19 (5.5)
High 125 (33.7) 0 (0) 125 (35.9)
Indeterminate 3 (0.8) 0 (0) 3 (0.9)
Adjuvant treatment
Chemotherapy only 110 (29.7) 11 (50.0) 99 (28.4) 0.032
Radiation only 55 (14.9) 2 (9.1) 53 (15.2) 0.756
Chemotherapy + Radiation 23 (6.2) 1 (4.5) 22 (6.3) 1.000
Hormone therapy 17 (4.6) 0 (0) 17 (4.9) 0.612
Abbreviations: FIGO International Federation of Gynecology and Obstetrics, TCGA The Cancer Genome Atlas; POLE polymerase ɛ, MSI microsatellite
instability, SD standard deviation
aMenopause was defined as amenorrhea for 6 months or more
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OS. Only advanced-stage disease (FIGO stage III-IV)
emerged as an independent predictor of poor prognosis
(adjusted HR, 3.509; 95% CI, 1.734–7.101; P < 0.001).
Table 2 also presents factors associated with PFS. In uni-
variate analysis, LYL1 gene amplification was associated
with poor PFS (P = 0.037), but its statistical significance
was not sustained in multivariate analysis. Advanced-
stage disease (FIGO stage III-IV) was identified as an in-
dependent poor prognostic factor for PFS (adjusted HR,
3.581; 95% CI, 1.981–6.473; P < 0.001).
We also stratified patients by tumor histologic type for
subgroup analysis. In those with endometrioid cancers
(n = 304), neither PFS (P = 0.070) nor OS (P = 0.323) dif-
fered significantly by LYL1 gene status (amplification vs.
non-amplification). However, results of multivariate ana-
lysis showed a trend towards worse PFS in the patients
with LYL1 gene amplification (adjusted HR, 4.093; 95%
CI, 0.926–18.012; P = 0.063) (Table 3).
DEGs in LYL1 amplified tumors
We performed GSEA pathway analysis of 993 genes
showing increased levels of expression in conjunction
with LYL1 amplification. Consequently, we found
significant upregulation of MAPK (P < 0.001), WNT
(P = 0.002), cell cycle (P = 0.004), and cancer-related
(P < 0.001) pathways (Fig. 3a, b). Of 993 DEGs, 384
cancer-related genes filtered via STRING database
were enriched through these pathways. MYC, CDK6,
PRKACA, and ERBB2 genes were found to frequently
interact with other cancer-related genes (Fig. 3c).
We also conducted GSEA according to histologic
types and TCGA classes (Additional file 1: Figure S1).
Among the four TCGA classes, only the high copy num-
ber group showed LYL1 amplifications, and cell prolifer-
ation pathway was significantly enriched in this group.
Compared to endometrioid type, cancer-related and cell
proliferation pathways and genes were more commonly
enriched in serous type (Additional file 2: Figure S2).
Discussion
In the present study, we used TCGA database analysis
to determine the potential impact of LYL1 gene amplifi-
cation on survival outcomes in patients with UCEC. Al-
though patients displaying LYL1 gene amplification
showed poorer PFS and OS compared to those with
non-amplification, multi-variate analyses failed to prove
it as an independent prognostic factor.
A number of studies have been similarly conducted to
date to identify novel biomarkers for patient survival in
various types of cancer. In particular, the prognostic im-
pact made by altered expression levels of L1CAM and
MYC, both homeobox gene family members, has been
researched through TCGA database analysis [14–16].
The LYL1 gene, a basic helix-loop-helix transcription
factor and a known oncogene in human and mouse can-
cers, is linked to many cancer-related properties, such as
angiogenesis [17–19]. Through genetic and epigenetic
modulations, the LYL1 gene acts to regulate cell prolifer-
ation and differentiation [8]. Both in vivo and in vitro
experiments have also demonstrated its interactions with
Fig. 2 Survival outcomes of patients with uterine corpus endometrial carcinoma, shown by LYL1 gene status: a overall survival and
(b) progression-free survival
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various oncogenes, such as MYC, TAL1, TAL2, and
LMO2 [20, 21].
Through our TCGA data analysis of LYL1 gene ampli-
fication in patients with UCEC, we discovered that over-
expressed cancer-related genes are enriched by MAPK,
WNT, and cell cycle pathways in such patients. Specific-
ally, MYC, CDK6, PRKACA, and ERBB2, all well-known
oncogenes and cancer markers, were overexpressed in
conjunction with LYL1 gene amplification. Both MYC
and ERBB2 have likewise shown associations with uter-
ine cancers in earlier studies [22–26]. Additionally, ex-
pression of PRKACA was positively correlated with LYL1
amplification (Pearson’s coefficient (r), 0.442).
Unfortunately, only advanced-stage disease emerged as
a significant marker of poor prognosis in multivariate
analyses. LYL1 gene amplification was not identified as
an independent prognostic factor. However, most of our
cohort had early-stage disease (FIGO stages I and II:
68.6% and 6.5%, respectively). According to Surveillance,
Epidemiology, and End Results data of the National
Cancer Institute, the 5-year survival rate for UCEC with
distant metastasis is a dismal 16.2%, compared with 95.3%
for disease confined to primary sites [27]. It is thus appar-
ent that the stage of UCEC impacts survival outcomes
dramatically, hindering analysis of amplification effects in
the current study population.
Fig. 3 Enrichment analysis of differentially expressed genes (DEGs), shown by LYL1 gene status: a significantly enriched pathway analysis in
upregulated 993 DEGs; b expression levels of enriched DEGs across LYL1 amplification; and (c) genes in significant gene networks bearing
simplified KEGG pathway annotations and grouped process-wise by commonest term prevailing in network (node size defined by degree
of interaction)
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The current study has several acknowledged limita-
tions, the first being that associations between the LYL1
gene and other genes or genetic mechanisms were not
validated, and the proteins expressed were not mea-
sured. Such proteogenomic studies would perhaps
underscore the effects of these genetic alterations and
the accuracy and completeness of genomic profiling. In
addition, further efforts to identify the genetic and epi-
genetic regulatory mechanisms of the LYL1 gene and an
evaluation of its efficacy as a prognostic indicator and
therapeutic target are warranted. In UCEC cell lines, the
LYL1 gene could be overexpressed or inhibited by
siRNA, determining subsequent flux in cell differenti-
ation, proliferation, or death. A LYL1 gene knock-out
patient-derived xenograft animal model is one possible
investigative approach. Another limitation was the sample
size of the LYL1 gene amplification group (n = 22), which
was too small for reasonable statistical inferences. Despite
these drawbacks, we were able to explore the prognostic
potential of the novel LYL1 gene in the setting of UCEC
using both TCGA and clinicopathologic data. LYL1 gene
amplification and its association with expression levels of
other genes were demonstrated as well.
Conclusions
In conclusion, LYL1 gene amplification is not identified
as an independent prognostic factor in UCEC. However,
we discovered that cancer-related pathways, such as
MAPK, WNT, and cell cycle pathways are upregulated
in patients with LYL1 amplification. Correlations be-
tween LYL1 amplification and increased expression
levels of cancer-related genes (MYC, CDK6, PRKACA,
and ERBB2) are also observed. Its potential for prognos-
tic indicator and therapeutic targeting may be implied
based on overexpression of such affiliated oncogenes.
Additional multi-omics and genome-wide data studies
are warranted.
Additional files
Additional file 1: Figure S1. Gene set enrichment analysis according to
histologic types and TCGA classes. (PNG 144 kb)
Additional file 2: Figure S2. Enriched genes of cancer-related and cell
proliferation pathways according to the two histologic types; serous and
endometrioid. (PNG 486 kb)
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